Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Provided By GlobeNewswire – Last update:

Quotes Stocks Mentioned

Article Mentions:

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union

Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly

Read more at globenewswire.com